baber/WOPTO huggingface dataset:
Patent NZ-503793-A (NZ)
Title: Novel aryloxy-alkyl-dialkylamines and processes for preparing these compounds
Inventor: RAVEENDRANATH PANOLIL
IPC: C07C217/20
Filed: 1998-10-14
Abstract: .A compound of formula (I) wherein: R' and R2 are H; C,-C,2 alkyl or Cl-C6 perfluorinated alkyl; X is halogen, -O-SO2-CH3, -O-SO2-CF3, or a moiety of structure (II); Z is -NO2, halogen, -CH3 or -CF3; A is selected from -O- , -S-, -SO-; m is an integer from 0 to 3; R3, R4, R5, and R6 are H, halogen, -NO2, alkyl, alkoxy, Cl-C6 perfluorinated alkyl, OH or C1-C4 esters or alkyl ethers thereof, CN, -O-R', -O-Ar, -S-R', -S-Ar, -SO-R', -SO-Ar, -SO2-R', -SO2-Ar, -CO-R', -CO Ar, -CO2-R', or-CO2-Ar; and Y is selected from; a) the moiety (III), wherein R7 and R8 are H, Cl-C6 alkyl, or phenyl; b) a five, six or seven membered heterocycle containing up to two heteroatoms selected from -O-, -NH-, -N(alkyl)-, -N=, and -S(O)n-, wherein n is 0-2, optionally substituted with 1-3 substituents of hydrogen, hydroxyl, halo, alkyl, trihalomethyl, alkoxy, trihalomethoxy, acyloxy, alkylthio,  alkylsulfinyl, alkylsulfonyl, hydroxyalkyl, phenyl optionally substituted with 1-3 alkyl, -CO2H, -CN, -CONHR1, -NH2, alkylamino,  dialkylamino, NHS02R1, -NHCOR1, or -NO2; c)  a bicyclic heterocycle  either bridged or fused and containing up to two heteroatoms selected from -O-, -NH-, -N(alkyl)-, and -S(O)n-, wherein n is 0-2, optionally substituted with 1-3 substituents selected from hydrogen, hydroxyl, halo, alkyl, trihalomethyl, alkoxy, trihalomethoxy, acyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, hydroxyalkyl, phenyl optionally substituted with 1-3 alkyl, -CO2H, -CN, -CONHR1, -NH2, alkylamino, dialkylamino, NHSO2R1, -NHCOR1, NO2; and the pharmaceutically acceptable salts thereof.
Patent NZ-506480-A (NZ)
Title: The c-myc coding region determinant-binding protein (crd-bp) and its nucleic acid sequence
Inventor: ROSS JEFFREY
IPC: C12Q1/68
Filed: 1999-03-05
Abstract: An ex-vivo method of diagnosing the presence or absence of cancer in a human patient comprising the steps of: (a) examining patient tissue for the CRD-BP expression levels and (b) comparing the result of step (a) with the expression level in non-cancerous tissue from the same source, wherein an increased CRD-BP level in the patient tissue compared to the non-cancerous tissue is diagnostic of cancer, and a method of inhibiting cancer cell growth comprising the step of eliminating or lowering the level of functional CRD-BP in the cancerous tissues is disclosed.
Patent NZ-508357-A (NZ)
Title: Combinations of protein farnesyltransferase and HMG COA reductase inhibitors and their use to treat cancer restenosis, psoriasis and proliferative cardiovascular disorders
Inventor: LEOPOLD JUDITH
IPC: A61K31/415
Filed: 1999-05-10
Abstract: Described are combinations of inhibitors of protein farnesyltransferase enzymes and HMG CoA reductases enzymes.  Also described are methods for the preparation and pharmaceutical compositions of the same, which are useful in preventing or treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.
Patent NZ-511116-A (NZ)
Title: HIV replication inhibiting pyrimidines
Inventor: AKEN KOEN JEANNE ALFONS VAN
IPC: C07D401/12
Filed: 1999-09-24
Abstract: A compound of formula (I-a), wherein: -b1=b2-C(R2a)=b3-b4= represents a carbocyclic ring optionally containing nitrogen atoms, q is 0-4, R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl or derivatives thereof, R2a is cyano, aminocarbonyl, or substituted C1-6alkyl, C2-6 alkenyl, or alkynyl, R2 is independently hydroxy, halo, or optionally substituted C1-6alkyl, C2-6 alkenyl, or alkynyl, carboxyl, cyano, nitro, amino, -S(=O)pR6, -NH-S(=O)pR6, -C(=O)R6, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R6, -C(=NH)R6, or a five-membered carbocyclic ring optionally containing nitrogen atoms, L is optionally substituted C1-10alkyl, C2-10alkenyl or alkynyl, C3-7cycloalkyl, or -X-R3 wherein R3 is phenyl pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, Q is hydrogen, C1-6alkyl, halo, or -NR4R5, Y can be the same radicals described for R2. The compounds as used in the manufacture of medicaments for the treatment of an infection of HIV-1 resistant to non-nucleoside reverse transcriptase inhibitors.
Patent NZ-519550-A (NZ)
Title: Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
Inventor: ANDO HOWARD YOSHIHISA
IPC: A61P9/14
Filed: 2001-01-11
Abstract: The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethylhexanoic acid monocalcium salt crystal forms 1 and 2 having the x-ray powder diffraction patters and NMR peaks as described in the specification.
Patent NZ-520102-A (NZ)
Title: Table for releasable clamping engagement with a pole on a pleasure boat
Inventor: MATHIESEN STEWART SYDNEY
IPC: A47B5/02
Filed: 2002-07-10
Abstract: Disclosed is a table for releasable clamping engagement with a pole of a pleasure boat such as a ski pole.
Patent NZ-520369-A (NZ)
Title: A separation process for producing titanium rich powder from metal matrix composite
Inventor: ZHANG DELIANG
IPC: C22C1/04
Filed: 2002-07-22
Abstract: A method of separating a component from a metal based composite, the method including the steps of increasing the size of a component within the metal based composite by heating the metal based composite, crushing the metal based composite and then separating of the increased sized component from the other components of the composite.
Patent NZ-522226-A (NZ)
Title: Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
Inventor: NOZULAK JOACHIM
IPC: A61P21/00
Filed: 2001-05-03
Abstract: A compound of formula I where: - n is 1 or 2 - R1, R2 and R3 are independently hydrogen or (C1-4)alkyl and A is a group of formulae a) to h). With reference to a) to h): - m is 1, 2, or 3 - X is O, S, NH or CH2 - R4 and R5 are independently hydrogen, halogen, hydroxy, (C1-4)alkyl, (C1-4)alkoxy, (C1-4)alkylthio, (C1-4)alkylamino, nitro, trifluoromethyl or phenyl. A process for the preparation of a compound of formula I is also disclosed. A compound and also a pharmaceutically acceptable composition comprising a compound of formula I, may be used to treat psychotic and neurodegnerative disorders.
Patent NZ-522359-A (NZ)
Title: A carpet weaving loom
Inventor: BURTON MICHAEL WINSPEAR
IPC: D05C15/16
Filed: 2001-05-11
Abstract: A carpet weaving loom comprises one or more tuft forming units (1), each of which is capable of supplying yarn tufts (26) of a number of different colours to a number of different weaving points sequentially. The or each of the tuft forming units (1) includes a demountable yarn carrier (2). In this way, when it is required to change the design of carpet being woven, or the creel (3) is exhausted, the or each yarn carrier (2) is simply replaced by another fed from a different creel (3). Preferably the creel (3) associated with the or each set of yarn carriers is itself removable from the remainder (6) of the loom and replaceable with the yarn carriers
Patent NZ-524165-A (NZ)
Title: System for providing communication between the interior and the exterior of a sterile compartment
Inventor: THILLY JACQUES
IPC: G21F7/005
Filed: 2001-08-13
Abstract: A system for making a connection between the interior and exterior of a compartment, comprising a door opening through the compartment wall, a connector body which can engage with the wall, and having a connection port through it, and a removable cover on the connector body. The body is engaged with the door opening, and an inner door within the compartment engages and removes the cover. A preferred construction creates a single line of confidence seal. The system is particularly suited for sterile compartments.
Patent NZ-525266-A (NZ)
Title: Method and system for organizing vendor information
Inventor: PALMER LISA M
IPC: G06Q30/00
Filed: 2001-10-11
Abstract: A plurality of accounts payable items (14) are communicated over communications links (24) to a global purchasing information repository (GPIR) (12) by account servers (19) and regional servers (18). A preparation application (16) unifies the representation of the accounts payable items and a GPIR application (20) associates categories (54) and buyer identifiers (56) with the accounts payable items based on criteria (70). A vendor alignment tool module (23) associates vendor identifiers (58) with vendor names (34) associated with the accounts payable items. The module also associates vendor groups (62) with the vendor identifiers based on relationships between the vendor identifiers. A plurality of reports (74) may be generated in response to the identifiers, groups and categories to provide information to a business regarding global expenditures and vendor relationships.
Patent NZ-530442-A (NZ)
Title: Method for controlling particular insect pests by applying anthranilamide compounds
Inventor: LAHM GEORGE PHILIP
IPC: C07D231/16
Filed: 2002-08-13
Abstract: A method for controlling lepidopteran, homopteran, hemipteran, thysanopteran and coleopteran insect pests is disclosed, which comprises contacting the insects or their environment with an arthropodicidally effective amount of a compound of formula (I), its N -oxide or an agriculturally suitable salt thereof wherein A and B and R1 through R8 are as defined in the specification. A bezoxazinone compound of formula (10) that is useful for preparation of a compound of formula (I) is also disclosed, wherein R4 through R8 are as defined in the specification.
Patent NZ-531102-A (NZ)
Title: File folder with portion projecting from an outer edge to allow for interleaving of a plurality of the file folders
Inventor: DEWAR BRUCE DUNCAN
IPC: B42F21/02
Filed: 2002-08-07
Abstract: A file folder (1) including a first (2) and second (3) rectangular panel, said panels (2, 3) joined along a common first edge defining a folding line (4), a projecting portion (7) integral with the first panel (2) and proximate a second edge (5) of the first panel, said projecting portion (7) oriented relative to a plane defined by the first panel so as to display a viewing face (8) of the projecting portion at an angle of at least 20 degrees to the first panel, said projecting panel having a complementary shape so as to permit interleaving of a plurality of the file folders.
Patent NZ-533174-A (NZ)
Title: Dough moulder
Inventor: WILLETT PAUL EATON
IPC: A21C7/02
Filed: 2003-09-25
Abstract: A dough moulder for producing moulded dough products of a desired size and/or shape is disclosed. The moulder includes a guide plate (155, 156) which are selectively insertable through respective pairs of slots (151, 152, 153) formed in a pressure rolling board (150). The guide plates (155, 156) extend through the pressure rolling board (150) to define a channel of selectable width depending on which pair of slots (151, 152, 153) is selected. The variable width channel enables dough products of a desired size and/or shape to be rolled.
Patent NZ-533629-A (NZ)
Title: Pyrido(2,1-A)isoquinoline derivatives as DPP-IV inhibitors
Inventor: GOBBI LUCA CLAUDIO
IPC: C07D471/04
Filed: 2002-12-20
Abstract: Disclosed are compounds of formula (I) wherein: R1 is lower alkyl, aryl, heteroaryl or lower alkyl substituted by cycloalkyl, by aryl or by heteroaryl; R2, R3 and R4 are each independently H, halogen, hydroxy, lower alkyl, lower alkoxy, or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl may optionally be substituted by lower alkoxycarbonyl, aryl or heterocyclyl; R5 is H, F, lower alkyl, or aryl; R6 is H, lower alkyl or hydroxyl-lower alkyl, or R5 and R6 together with the carbon atoms to which they are attached form a five or six membered saturated carbocyclic ring; R7 is H, R or lower alkyl. The disclosed compounds are dipeptidyl peptidase IV (DPP-IV) inhibitors. They are useful for the treatment or prophylaxis of diseases associated with the DPP-IV enzyme such as diabetes, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, hypertension, diseases where a diuretic agent has a beneficial effect, obesity and/or metabolic syndrome.
Patent NZ-536287-A (NZ)
Title: Use of succinimide and maleimide cytokine inhibitors to reduce the levels of TNF in a mammal
Inventor: MULLER GEORGE W
IPC: A61M5/31
Filed: 1996-10-04
Abstract: Disclosed herein are succinimide and maleimide cytokine inhibitor compounds selected from any one of: N-[1-(3,4-dimethoxyphenyl)-2-carbomethoxy-methane]-3-carboxypropionamide, Methyl 3-succinimidyl-(3,4-dimethoxypbenyl) propionate, Methyl 3-(cis-1,2,5,6-tetrahydrophthalimidol-3-(3,4-dimethoxyphenyl) propionate, Methyl 3-(cis-hexahydrophthalimido)-3-(3,4-dimethoxyphenyl)propionate, Methyl N-(maleic acid)-3-amino-3-(3',4'-dimethoxyphenyl)propionate, Methyl 3-maleimido-3-(3,4-dimethoxyphenyl)propionate, Methyl 3-(3,4,5,6-tetrahydrophthalimido)-3-(3,4-dimethoxyphenyl)propionate, Methyl 3-(3,4,5,6-tetrahydrophthalimido-3-(3'-ethoxy-4'methoxyphenyl) propionate, 1-(3,4,5,6-Tetrahydrophthalimido)-1-(3'-ethoxy-4'methoxyphenyl)propane; or stereo isomers thereof. These compounds are suitable for reducing levels of TNFalpha in a mammal, inhibiting TNFalpha-activated retrovirus replication in a mammal, and for inhibiting phosphodiesterase in a mammal.
Patent NZ-537949-A (NZ)
Title: Mechanical heart valve with details of winglets of leaflets
Inventor: STEINSEIFER ULRICH
IPC: A61F2/24
Filed: 1999-06-02
Abstract: The present invention relates to an improved "trileaflet" mechanical heart valve (100) and an improved leaflet (110) for use with such valve. The valve (100) and leaflet (110) of the present invention provide improved flow characteristics, minimize blood clotting behind the leaflets, and provide more natural opening and closing times. The valve includes a valve housing (105) which contains pivot/hinge mechanism (130, 200) for allowing rotation of and retention of the leaflets (110). The valve housing (105) also includes windows or openings (125) which allows for complete washing of the pivot/hinge mechanism (130, 200) as well as the leaflets (110). The novel leaflets (110) are airfoil-like having a complex S-shaped curvature on their outer surface. This novel geometry, when combined with the location of the leaflet's pivot axis, causes a tendency for the leaflet (110) to rotate towards the closed position. Thus, the leaflet (110) begins to close much earlier than a conventional leaflet and is substantially closed before the flow reverses, similar to the function of a natural valve. This application relates to the geometry and functioning of winglet portions (205) of the leaflets.
Patent NZ-538265-A (NZ)
Title: Sperm cell process system
Inventor: SCHENK JOHN L
IPC: A61K35/52
Filed: 2003-07-22
Abstract: Disclosed is a method of separating sperm cells, comprising: a. obtaining semen from a male of a species of mammal which contains a plurality of sperm cells; b. incubating said semen at a temperature above which sperm cell membrane lipids transition from a liquid phase to gel phase for at least one hour, said temperature comprising between about 5 degrees C and about 25 degrees C, c. determining a sperm cell sex characteristic of a plurality of said sperm cells; d. separating said sperm cells based upon said sperm cell sex characteristic; and e. collecting separated sperm cells.
Patent NZ-538275-A (NZ)
Title: A delivery system and a manufacturing process of a delivery system
Inventor: HALLINEN ESA
IPC: A61B17/42
Filed: 2003-09-04
Abstract: Disclosed is a delivery system comprising a body construction (7) and at least one capsule (8) containing a pharmaceutical composition, the capsule having at least a first end and a second end. The body construction has at least two locking parts (9, 10), each locking part having at least a first end and a second end, the first end of each locking part having a surface adapted to face and cover one of the at least first and second ends of the capsule, the diameter of at least one of the locking parts varying along its length between the first end and the second end, and the capsule is mounted between the at least two locking parts. Also disclosed is a manufacturing process of the delivery system.
Patent NZ-539014-A (NZ)
Title: Biomasses obtained from a fungal or microalgal culture containing the acids PUFAs ARA, DHGLA, DHA or EPA, pressed in the dry state so as to obtain a first press oil and a cake
Inventor: BERTHOLET RAYMOND
IPC: A61K8/02
Filed: 2003-08-07
Abstract: Disclosed is a stable oil containing LC-PUFAs in the form of triacylglycerols, in particular arachidonic acid (ARA), dihomogammalinolenic acid (DHGLA), docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA). The oils may be prepared by direct pressing of one or more biomasses obtained from the culture of a microorganism, especially of a fungus or of a microalga containing the acids ARA, DHGLA, DHA or EPA leading to a first press oil and by bringing a carrier oil entering into the composition of a foodstuff, a cosmetic or pharmaceutical product, into contact with the biomass cake, followed by pressing leading to a second press oil, and then by combining the pressed oils and refining the mixture under controlled conditions.
Patent NZ-541658-A (NZ)
Title: Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
Inventor: COHEN-VERED SHARON
IPC: A61K38/08
Filed: 2004-01-14
Abstract: Disclosed is a pharmaceutical composition comprising: an, aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a) peptide comprising at least 12 and at most 30 consecutive amino acids having a sequence corresponding to (i) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a human monoclonal anti-DNA 16/6 Id antibody, or (ii) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease response in mice, or b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, or c) a peptide comprising consecutive amino acids having a sequence of any of and b), or at least two of the sequences in (a)(1), (a) (ii) and (b)(i) through (b)(x), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a) (i), (a) (ii) and (b) (i) through (b)(x); and a solubility enhancer, wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier; and wherein the composition has a pH between 4 and 9, and a use of alleviating symptoms of SLE in a human by administering an effective amount of the composition.
Patent NZ-542177-A (NZ)
Title: Cyclic benzimidazoles for use against gastrointestinal disorders
Inventor: BUHR WILM
IPC: C07D491/04
Filed: 2004-04-02
Abstract: Disclosed is a compound of formula (I) or a pharmaceutically acceptable salts thereof, wherein X is O or NH, and wherein the rest of the subtituents are disclosed in the specification. Also disclosed is the suitability of the above compound for preventing and treating gastrointestinal disorders.
Patent NZ-545404-A (NZ)
Title: Human skin equivalents expressing exogenous polypeptides
Inventor: CENTANNI JOHN M
IPC: A61K35/12
Filed: 2004-07-30
Abstract: Provided is the use of an isolated keratinocyte and an expression vector comprising a DNA sequence encoding an exogenous antimicrobial polypeptide operably linked to a regulatory sequence, in the manufacture of a skin equivalent that expresses said exogenous antimicrobial polypeptide for the treatment of a wound type selected from the group comprising venous ulcers, diabetic ulcers, pressure ulcers, burns, ulcerative colitis, mucosal injuries, internal injuries, and external injuries; wherein said expression vector is introduced into said keratinocyte.
Patent NZ-550823-A (NZ)
Title: Diversion system for foul flush of storm water runoff
Inventor: YOUNG GEOFFREY PAUL
Filed: 2006-10-25
Abstract: A method of diverting fluid from a runoff event on a catchment area is disclosed. The system ensures that the first flush of contaminated water is diverted away from a storage system. The method consists of: (a) Collecting fluid from the catchment area into a collection chamber (2). The collection chamber (2) including a partition (8) forming a first chamber (9) containing an inlet (3) and a first outlet (6) to a first outlet system, and a second chamber (10) containing a second outlet (11) to a second outlet system, wherein the height of the partition is not less than a cut-off height and less than the height of the collection chamber (2). (b) Allowing the fluid to flow to a diversion system in the first chamber (9). (c) Diverting via the diversion system an initial volume of the fluid into the first outlet system. (d) Continuing to divert fluid into the first outlet system if a flow rate of the fluid into the collection chamber (9) is below a pre-set rate. (e) Subsequently diverting the fluid into the second outlet system if the flow rate of fluid into the collection chamber (9) exceeds the pre-set rate by closing the first outlet (6) when the fluid level in the first chamber (9) reaches the cut-off height and allowing the fluid to flow into the second chamber (10) and out through the second outlet (11).
Patent NZ-551669-A (NZ)
Title: Combinations comprising antimuscarinic agents and PDE4 inhibitors
Inventor: GRAS ESCARDO JORDI
IPC: A61K31/167
Filed: 2005-05-31
Abstract: Disclosed is a combination comprising the M3 muscarinic receptor antagonist (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt with a pharmaceutically acceptable anion or a mono or polyvalent acid, and a PDE4 inhibitor. Also disclosed is the use of the above combination for treating a respiratory disease which responds to M3 antagonism, such as asthma or chronic obstructive pulmonary disease.
Patent NZ-553434-A (NZ)
Title: Prostaglandin derivatives for treating gastrointestinal disorder
Inventor: UENO RYUJI
IPC: A61P1/14
Filed: 2005-09-01
Abstract: Disclosed is the use of a prostaglandin compound represented by Formula (I) and/or its tautomer thereof, wherein the substituents are as defined in the specification, for manufacturing a pharmaceutical composition for the long term treatment of gastrointestinal disorders in a human subject, wherein the composition is to be administered to the patient in need thereof for over four weeks.
Patent NZ-554391-A (NZ)
Title: Display for public use
Inventor: OGOREVC ANDRAZ
Filed: 2005-05-10
Abstract: A display for public use is provided. The display includes a hollow stand, a housing, a computer and an air conditioning device. The computer is arranged inside the housing. The air conditioning device is arranged inside the hollow stand. An evaporator of the air conditioning device is connected to an opening in the floor panel of the housing, while a compressor of the air conditioning device is arranged on the floor panel of the stand.
Patent NZ-554796-A (NZ)
Title: A pelagic trawl door constructed in a V configuration with an aspect ration of at least 2:1
Inventor: VIGFUSSON GUDMUNDUR
IPC: A01K73/045
Filed: 2005-11-01
Abstract: A trawl pelagic door (10) for use with a trawl net is disclosed. The door (10) significantly reduces the drag of a total trawl system, thus conserving fuel. The door (10) has leading and trailing edges and an upper (32) and lower section (34). Each section has a main deflector body with an outer side convex surface and has a leading and trailing edges. Each main deflector body has at least one curved slat on the leading edge, whose leading edge is disposed forward of the leading edge of a main deflector body. The aspect ratio of the door (10) is at least 2:1. The two main deflector bodies and their associated slats lie in different planes that diverge and have an angle of less than one hundred eighty degrees. The relationship between slat and main deflection body curvature and the relative locations of these parts is disclosed.